Erratum to: Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus

Lawrence Blonde · Zinnia T. San Juan

© Springer Healthcare 2013

Erratum to: Blonde L, San Juan ZT. Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Adv Ther. 2012;29(1):1–13.

The authors of the above-mentioned paper would like to make the following adjustment to their article.

In the published Table 2, the first column of the seventh row reads ‘Sitagliptin + metformin.’ This should read ‘Saxagliptin + metformin.’ The corrected word can be seen in the table below.

The authors thank Springer Healthcare for publishing the correction.

Table 2 Effects of combination versus monotherapy on glycemic parameters in patients with type 2 diabetes mellitus (T2DM) for two-drug regimens now available in fixed-dose combinations (FDCs) (*continued on next page*).

Treatment	Maximum daily doses, mg (via titration as per protocol)	A1C, %		Fasting plasma glucose, mg/dL	
		Baseline	Change	Baseline	Change
Glucovance® (metformin + glyburide) 20-week study of initial FDC therapy ²³	MET 1000/GLY 5	8.25	−1.48*	177	−42†
	MET 2000/GLY 10	8.18	−1.53*	175	−40†
	MET 2000	8.26	−1.03	176	−21
	GLY 10	8.21	−1.24	179	−36
	Placebo	8.21	−0.21	177	+5
Actoplus Met® (pioglitazone + metformin) 24-week study of initial FDC therapy ²⁴	PIO 30/MET 1700	8.89	−1.83‡	177.5	−39.9*
	PIO 30	8.69	−0.96	170.8	−22.2
	MET 1700	8.65	−0.99	170.5	−24.8
Avandamet® (rosiglitazone + metformin) 32-week study of initial FDC therapy ²⁵	ROSI 8/MET 2000	8.9	−2.3‡	202	−74‡
	ROSI 8	8.8	−1.6	193	−47
	MET 2000	8.8	−1.8	198	−50

Table 2 continued

Treatment	Maximum daily doses, mg (via titration as per protocol)	A1C, %		Fasting plasma glucose, mg/dL	
		Baseline	Change	Baseline	Change
Avandaryl® (rosiglitazone + glimepiride)	ROSI 4/GLIM 4	9.0	−2.41‡	207	−70‡
28-week study of initial FDC therapy ²⁶	ROSI 8/GLIM 4	9.2	−2.52‡	214	−80‡
	ROSI 8	9.1	−1.75	212	−57
	GLIM 4	9.0	−1.72	211	−42
Metaglip® (glipizide + metformin)	GLIP 20/MET 2000	8.7	−1.3§	194	NR§
18-week study of initial FDC therapy ²⁷	GLIP 30	8.9	−0.4	204	NR
	MET 2000	8.7	−0.2	191	NR
Metformin + repaglinide (now available as Prandimet®)	MET ~1800 /REPAG 4	8.3	−1.41¶	184	−39.3¶
16- to 20-week study of repaglinide added to ongoing metformin (individual pills) ²⁸	MET ~1800	8.6	−0.33	195	−4.5
	REPAG 4	8.6	−0.38	174	+8.6
Saxagliptin + metformin (now available as Kombiglyze XR®#)	SAXA 5/MET 2000	9.4	−2.5**	199	−60††
24-week study of initial dual combination therapy (individual pills) ²⁹	SAXA 10/MET 2000	9.5	−2.5**	204	−62**
	SAXA 10	9.6	−1.7	201	−31
	MET 2000	9.4	−2.0	198	−47
Sitagliptin + metformin (now available as Janumet®)	SITA 100/MET 1000	8.79	−1.40§	203.9	−47.1§
24-week study of initial dual combination therapy (individual pills) ³⁰	SITA 100/MET 2000	8.76	−1.90§	196.7	−63.9§
	SITA 100	8.87	−0.66	201.4	−17.5
	MET 1000	8.90	−0.82	205.2	−27.3
	MET 2000	8.68	−1.13	197.0	−29.3
	Placebo	8.68	+0.17	196.3	+5.8

* $P < 0.01$ versus all monotherapies.

† $P \leq 0.001$ versus MET monotherapy.

‡ $P < 0.0001$ versus all monotherapies.

§ $P \leq 0.001$ versus all monotherapies.

||Prestudy dosage of MET maintained. Mean daily MET dose presented.

¶ $P < 0.05$ versus all monotherapies.

#SAXA is not approved at 10 mg; Kombiglyze XR is available with SAXA 2.5 mg plus MET 1000 mg or with SAXA 5 mg plus MET 500 or 1000 mg.

** $P < 0.0001$ versus MET monotherapy.

†† $P = 0.0002$ versus MET monotherapy.

A1C=glycated hemoglobin; GLIM=glimepiride; GLIP=glipizide; GLY=glyburide; MET=metformin; NR=value not reported; PIO=pioglitazone; REPAG=repaglinide; ROSI=rosiglitazone; SAXA=saxagliptin; SITA=sitagliptin; XR=extended-release formulation.